Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

The primary objective of this study was to systematically review and analyse epidemiological
studies of the prevalence and incidence of atopic dermatitis (AD) during childhood and …

Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …

Summary Background The Global Burden of Disease (GBD) Study provides an annually
updated resource to study disease‐related morbidity and mortality worldwide. Objectives …

Background Little is known on the current global prevalence of atopic dermatitis (AD) in the
pediatric population. Objective To estimate the real-world global prevalence of AD in the …

Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …

Introduction Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately
20% of the global population. Few studies describe the burden of the totality of these …

Background Dupilumab, the first biological drug to be approved for the treatment of
moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy …

Importance Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy …

Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The
objectives of this study were to determine the prevalence of atopic dermatitis in the …